Clinical Trial Update: Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating the combination of anlotinib with nivolumab for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• nivolumab (nivolumab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN